Basic Search
|
Summaries
|
Advanced Search
Violation Tracker Current Parent Company Summary
Current Parent Company Name: Astellas Pharma
Ownership Structure: publicly traded
Headquartered in: Japan
Major Industry: pharmaceuticals
Specific Industry: pharmaceuticals
Penalty total since 2000: $329,802,884
Number of records: 11
Top 5 Offense Groups (Groups Defined) | Penalty Total | Number of Records |
government-contracting-related offenses | $208,930,000 | 7 |
competition-related offenses | $120,865,384 | 3 |
miscellaneous offenses | $7,500 | 1 |
Top 5 Primary Offense Types | Penalty Total | Number of Records |
False Claims Act and related | $208,930,000 | 7 |
price-fixing or anti-competitive practices | $120,865,384 | 3 |
campaign finance violation | $7,500 | 1 |
Notes: Parent-subsidiary linkages are based on relationships current as of the latest revision listed in the
Update Log, which may vary from what was the case when a violation occurred. The penalty totals are adjusted to account for the fact that the individual entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. The totals are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the list below.
Links: For a summary of this company's regulatory penalties in more than 50 other countries, see its Violation Tracker Global summary page
here.
Subsidy Tracker data on financial assistance to this company by federal, state and local government agencies can be found
here.
Individual Penalty Records:
Click on the company or penalty amount for more information on each case.
Company | Primary Offense Type | Year | Agency | Penalty Amount |
Astellas Pharma US Inc. | False Claims Act and related | 2019 | DOJ_CIVIL | $100,000,000 |
Astellas Pharma US, Inc. | price-fixing or anti-competitive practices | 2015 | private lawsuit-federal | $98,000,000 |
OSI Pharmaceuticals LLC | False Claims Act and related | 2016 | DOJ_CIVIL | $67,000,000 |
OSI Pharmaceuticals LLC | False Claims Act and related | 2016 | DOJ_CIVIL | $33,500,000 |
Astellas Pharma US, Inc. | price-fixing or anti-competitive practices | 2016 | private lawsuit-federal | $13,250,000 |
Fujisawa Healthcare, Inc. | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $9,615,384 |
Astellas Pharma US Inc. | False Claims Act and related | 2014 | DOJ_CIVIL | $7,300,000 |
Astellas Pharma US Inc. | False Claims Act and related | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,100,000 |
OSI Pharmaceuticals LLC | False Claims Act and related | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $2,200,000 |
Astellas | False Claims Act and related | 2013 | LA-AG | $1,130,000 |
Astellas Pharma US, Inc. | campaign finance violation | 2022 | FEC | $7,500 |